Erschienen in:
01.11.2010 | Original Paper
Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes
verfasst von:
Qingqu Guo, Muxing Kang, Bo Zhang, Ying Chen, Xin Dong, Yulian Wu
Erschienen in:
Journal of Cancer Research and Clinical Oncology
|
Ausgabe 11/2010
Einloggen, um Zugang zu erhalten
Abstract
Background
The relationship between diabetes and pancreatic cancer has been established by more than several decades of research. However, serum levels of CEA and CA 19-9 in diabetic pancreatic cancer has not been shown.
Methods
Preoperative serum levels of CEA and CA 19-9 and clinicopathological characteristics were retrospectively analyzed in 79 with or 229 without diabetes in pancreatic ductal adenocarcinoma (PDA) patients.
Results
Of the 308 PDA patients enrolled, 79 (25.6%) patients had diabetes. The percentage of new-onset diabetes (i.e. <24 months in duration) was 57% (45/79) in PDA patients coupled with diabetes. Among diabetic PDA patients, mean total bilirubin and fasting blood glucose significantly increased in comparison with control groups (8.54 ± 14.88 vs. 4.16 ± 6.12; 170.22 ± 106.96 vs. 95.84 ± 15.76; P < 0.05). No significant differences were observed in mean levels of serum CA 19-9 and CEA levels between two groups. However, when the value of CEA and CA 19-9 was analyzed as a dichotomous variable, elevated CEA (≥5 ng/ml) and CA 19-9 (≥500 U/ml) levels were strongly correlated with the presence of diabetes in PDA patients.
Conclusion
Elevated CEA (≥5 ng/ml) and CA19-9 (≥500 U/ml) levels have an association with diabetic pancreatic cancer. New-onset diabetes combined with higher CA 19-9 and/or CEA might be regarded as a useful tool to screen early pancreatic cancer.